Cancer treatment method with nanocomposite
A method of cytotoxically treating cancer with aluminum silicate nanorods (SNRs) including aluminum, iron, magnesium, oxygen, potassium, and oxygen comprises contacting the SNRs at a concentration of 0.5 to 2 μg/mL with a cancerous sample. The aluminum silicate nanorods have a longest dimension of 100 nanometers (nm) to 5500 nm and a diameter of 20 nm to 250 nm. The SNRs are porous with a pore size of 1 nm to 12 nm and include cisplatin in an amount of 20 to 300 mg/g. The cancerous sample has a reduced cell viability after the contacting.
1. A method of cytotoxically treating cancer with a nanocomposite, including:
contacting aluminum silicate nanorods at a concentration of 0.5 to 2 μg/mL with a cancerous sample,
wherein the aluminum silicate nanorods comprise aluminum, iron, magnesium, oxygen, and potassium,
wherein the aluminum silicate nanorods have a longest dimension of 100 to 5500 nm and a diameter of 20 to 250 nm,
wherein the aluminum silicate nanorods are porous with a pore size of 1 to 12 nm,
wherein the aluminum silicate nanorods include cisplatin in an amount of 20 to 300 mg/g, wherein at least a portion of the cisplatin is encapsulated by the aluminum silicate nanorods,
wherein the cancerous sample has a reduced cell viability after the contacting.
2. The method of claim 1 , wherein the aluminum silicate nanorods are rolled nanosheets of an exfoliated glauconite.
3. The method of claim 1 , wherein the aluminum silicate nanorods are made by a process including:
grinding a glauconite;
dispersing and stirring the ground glauconite in a polar solvent for 70 to 75 h,
wherein the dispersing and stirring breaks intermolecular bonds in the glauconite,
washing the dispersed glauconite 4 to 6 times for 10 to 30 minutes each time with methanol to form a methoxy glauconite;
immersing and stirring the methoxy glauconite in an aqueous cetyltrimethylammonium bromide solution for 45 to 50 h at 800 to 1200 rpm to form exfoliated methoxy glauconite layers,
sonicating the exfoliated methoxy glauconite layers at a power supply of 230 to 250 W for 90 to 100 h to form a product,
wherein the sonicating rolls the exfoliated methoxy glauconite layers into the product,
filtering, washing with deionized water, and drying the product at 50 to 70 degrees Celsius (° C.) to form the aluminum silicate nanorods.
4. The method of claim 3 , wherein the polar solvent is a 5:95 to 25:75 volume to volume (v/v) ratio mixture of water to dimethyl sulfoxide.
5. The method of claim 1 , wherein the cisplatin is present on an outer surface of the aluminum silicate nanorods.
6. The method of claim 1 , wherein the cisplatin interacts with the pores and the outer surface of the aluminum silicate nanorods through hydrogen bonding and van der Waals forces.
7. The method of claim 1 , wherein the aluminum silicate nanoroads are formed by mixing the nanorods with a cisplatin solution at a pH of 2 to 10.
8. The method of claim 1 , wherein the aluminum silicate nanorods are formed by mixing the nanorods with cisplatin for 0.5 to 25 h.
9. The method of claim 1 , wherein the aluminum silicate nanorods have a saturation loading capacity of 200-350 milligram of cisplatin per gram of nanorod (mg/g).
10. The method of claim 1 , wherein the aluminum silicate nanorods have a density of loading receptor value of 12 to 17 mg/g.
11. The method of claim 1 , wherein the aluminum silicate nanorods have binding site and each binding site accommodates 15 to 25 molecules of cisplatin.
12. The method of claim 1 , wherein the aluminum silicate nanorods release cisplatin for 190 to 210 h at a pH of 5.4 to 5.6.
13. The method of claim 1 , wherein the aluminum silicate nanorods release cisplatin for 100 to 120 h in a solution at a pH of 7.3 to 7.5.
14. The method of claim 1 , wherein the aluminum silicate nanorods have a surface area of 120 to 130 m 2 /g.
15. The method of claim 1 , wherein the aluminum silicate nanorods have an average pore diameter of 3 to 5 nm.
16. The method of claim 1 , wherein the aluminum silicate nanorods have an uptake energy for the cisplatin of −6 to −2 KJ/mol.
17. The method of claim 1 , wherein the cell viability of the cancerous sample is 2 to 5% after 48 h of contacting.
18. The method of claim 1 , wherein the cell viability of the cancerous sample is 0.5 to 1.0% after 72 h of contacting.